SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

Completed · Phase 3 · Has a placebo group

Conditions studied: Advanced Stage Parkinson's Disease

In brief

This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.

Key facts

Study ID
NCT00406588
Run by
Solvay Pharmaceuticals
People needed
295
Starts
2007-03-01
Expected to finish
2008-05-01
Last updated by the study team
2015-02-27

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.